GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Yahoo! Finance
The randomised, double-blind, placebo-controlled study has been assessing uproleselan plus one of two chemotherapy regimens: mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI). Patients were given either uproleselan or a placebo over one cycle of induction and up to three cycles of consolidation if applicable. The study included 388 patients enrolled across 70 sites in nine countries. Its primary endpoint was overall survival without censoring for transplant, while secondary endpoints included the incidence of various oral mucositis, complete remission rate and remission rate. According to the findings, the study did not show a statistically significant improvement in overall survival when uproleselan was combined with chemotherapy compared to chemotherapy alone. Despite not meeting the primary endpoint, subjects treated with uproleselan experienced a median overall survival of 13 months, as opposed to 12.3 months in the placebo arm
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Uproleselan's failed Phase III AML trial shakes up GlycoMimetics' future [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at Capital One Financial Co. from an "overweight" rating to an "equal weight" rating.MarketBeat
- We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
GLYC
Earnings
- 5/9/24 - Miss
GLYC
Analyst Actions
- 3/27/24 - HC Wainwright
GLYC
Sec Filings
- 5/9/24 - Form 10-Q
- 5/8/24 - Form SC
- 5/6/24 - Form 8-K
- GLYC's page on the SEC website